DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform

Summary

DualityBio entered a global collaboration and license agreement with Genentech to develop next-generation antibody-drug conjugates (ADCs) using DualityBio's proprietary DUPAC payload platform, with Genentech assuming clinical development and commercialization responsibilities.